Newsroom

MAILAND--(BUSINESS WIRE)--SciencePower, ein Unternehmen für postbiotische Plattformen der nächsten Generation, hat heute den Abschluss einer Lizenzvereinbarung mit der Mayo Clinic bekannt gegeben. Die Vereinbarung sieht eine gemeinsame Forschungsinitiative unter der Leitung von Forschern der Mayo Clinic vor, um das Potenzial der proprietären postbiotischen Zusammensetzungen von SciencePower in der Brustkrebsbiologie zu sondieren. Ziel der Zusammenarbeit ist es, den Einfluss bestimmter mikrobiom...

MILAN--(BUSINESS WIRE)--SciencePower, une société de plateforme postbiotique de nouvelle génération, annonce aujourd'hui avoir conclu un accord de licence avec Mayo Clinic. L’accord vise une recherche collaborative menée par des chercheurs de la Mayo Clinic afin d’explorer le potentiel des compositions postbiotiques propriétaires de SciencePower en biologie du cancer du sein. La collaboration se concentrera sur la compréhension de la façon dont des compositions spécifiques dérivées du microbiom...

MILAAN--(BUSINESS WIRE)--SciencePower, een bedrijf dat zich richt op een postbioticaplatform van de volgende generatie, heeft vandaag aangekondigd dat het een licentieovereenkomst is aangegaan met Mayo Clinic. Deze overeenkomst maakt gezamenlijk onderzoek onder leiding van onderzoekers van Mayo Clinic mogelijk om het potentieel van de gepatenteerde postbiotische samenstellingen van SciencePower in de biologie van borstkanker te verkennen. De samenwerking is gericht op het begrijpen van de wijze...

MILÁN--(BUSINESS WIRE)--SciencePower, una empresa de plataforma posbiótica de próxima generación, anunció hoy que ha suscrito un acuerdo de licencia con Mayo Clinic. El acuerdo hace posible la investigación colaborativa liderada por investigadores de Mayo Clinic con el objetivo de explorar el potencial las composiciones posbióticas patentadas de SciencePower en biología de cáncer de mama. La colaboración se enfocará en entender de qué forma las composiciones derivadas de microbiomas afectan las...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does not currently own in OneOncology, a physician-led national platform empowering independent medical specialty practices rooted in oncology, from TPG, a leading global alternative asset management firm. “We are excited to accelerate our acquisition of OneOncology, which will advance our management services...

BETHESDA, Md.--(BUSINESS WIRE)--Pebblebrook Hotel Trust Declares Dividends for Fourth Quarter 2025...

MÉRIGNAC, France--(BUSINESS WIRE)--Companion Spine, the French-American specialist in surgeon innovated spine implant surgery, announced that the U.S. Food and Drug Administration (the “FDA”) has approved the DIAM™ Spinal Stabilization System (P240043). DIAM™ Spinal Stabilization System is the first posterior motion-preserving device approved in the U.S. for the treatment of moderate to severe primary low back pain secondary to DDD at a single lumbar level (L2–L5) in patients who remain symptom...

PALO ALTO, Calif.--(BUSINESS WIRE)--C1 Fund Inc. (NYSE: CFND) (the “Fund”), a publicly traded closed-end investment company providing public-market investors with exposure to late-stage digital-asset services and technology companies, today announced that it has acquired a position in Consensys, a leading global blockchain software company and foundational contributor to the Ethereum ecosystem. Consensys is widely recognized for its suite of infrastructure products supporting developers, enterp...

CALABASAS, Calif.--(BUSINESS WIRE)--ARDRI, a technology-forward Non-QM and Business Purpose mortgage lender, is proud to announce the appointment of Wesley Olison as Vice President of Wholesale Production. With more than 20 years of proven mortgage and finance leadership experience, Wesley joins ARDRI at a pivotal moment in the company’s expansion, bringing a powerful blend of strategic vision, operational insight, and results-driven leadership. Wesley is known for his decisive, growth-driven l...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aviceda Therapeutics (“the Company” or “Aviceda”), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b study evaluating AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The primary endpoint analysis showed no statistical difference in the rate of change in GA area between AVD-104 versus monthly avacincaptad pego...